Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1994 1
1996 1
1997 2
2002 1
2010 1
2011 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
MDL 27,531 selectively reverses strychnine-induced seizures in mice.
Kehne JH, Kane JM, Miller FP, Ketteler HJ, Braun DL, Senyah Y, Chaney SF, Abdallah A, Dudley MW, Ogden AM, et al. Kehne JH, et al. Among authors: senyah y. Br J Pharmacol. 1992 Aug;106(4):910-6. doi: 10.1111/j.1476-5381.1992.tb14434.x. Br J Pharmacol. 1992. PMID: 1327393 Free PMC article.
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.
Black MD, Stevens RJ, Rogacki N, Featherstone RE, Senyah Y, Giardino O, Borowsky B, Stemmelin J, Cohen C, Pichat P, Arad M, Barak S, De Levie A, Weiner I, Griebel G, Varty GB. Black MD, et al. Among authors: senyah y. Psychopharmacology (Berl). 2011 May;215(1):149-63. doi: 10.1007/s00213-010-2124-0. Epub 2010 Dec 22. Psychopharmacology (Berl). 2011. PMID: 21181124
Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist.
Baron BM, Harrison BL, Kehne JH, Schmidt CJ, van Giersbergen PL, White HS, Siegel BW, Senyah Y, McCloskey TC, Fadayel GM, Taylor VL, Murawsky MK, Nyce P, Salituro FG. Baron BM, et al. Among authors: senyah y. Eur J Pharmacol. 1997 Apr 4;323(2-3):181-92. doi: 10.1016/s0014-2999(97)00045-9. Eur J Pharmacol. 1997. PMID: 9128837
Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, van Giersbergen PL, McCloskey TC, Johnson MP, McCarty DR, Poirot M, Senyah Y, Siegel BW, Widmaier C. Kehne JH, et al. Among authors: senyah y. J Pharmacol Exp Ther. 1996 May;277(2):968-81. J Pharmacol Exp Ther. 1996. PMID: 8627580